Ultragenyx Pharmaceutical (RARE) Operating Income Growth (5y) (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) Operating Income Growth (5y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Ultragenyx Pharmaceutical 2.71 Bn 2.30 Bn 106.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -9.66%
Dec 31, 2025 -3.35%
Sep 30, 2025 -27.70%
Jun 30, 2025 -11.34%
Mar 31, 2025 -3.45%
Dec 31, 2024 -5.30%
Sep 30, 2024 -2.26%
Jun 30, 2024 -0.68%
Mar 31, 2024 -10.76%
Dec 31, 2023 -6.17%
Sep 30, 2023 -10.11%
Jun 30, 2023 -9.29%
Mar 31, 2023 -9.82%
Dec 31, 2022 -8.50%
Sep 30, 2022 -21.87%
Jun 30, 2022 -12.54%
Mar 31, 2022 -14.33%
Dec 31, 2021 -7.77%
Sep 30, 2021 -6.43%
Jun 30, 2021 -7.35%